Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
JIB
GLOBETECH PUBLISHING

New Lab Technology Will Boost Cell Therapy Applications

By BiotechDaily International staff writers
Posted on 25 Nov 2013
Image: The Xuri Cell Expansion System W25 (Photo courtesy of GE Healthcare).
Image: The Xuri Cell Expansion System W25 (Photo courtesy of GE Healthcare).
A newly released family of cell culture systems was designed specifically to support and advance the growing field of cell therapy.

The Xuri Cell Expansion System W25 is the first member of GE Healthcare's (Chalfont St. Giles, United Kingdom) new hi-tech cell culture systems to be released for sale.

This system comprises a reliable and intuitive device for expansion of human cell cultures for cellular therapy purposes. It employs single-use, functionally closed disposables to minimize risk of contamination. The Xuri system can accommodate working volumes from as little as one liter—appropriate for growing high-density cell cultures—with room to expand up to 25 liters. The system is based on GE Healthcare's WAVE rocking technology that provides mixing and aeration. The Xuri system is functionally closed, which minimizes the risk of cell contamination while allowing the culture to reach high cell densities.

The Xuri Cell Expansion System W25 is enhanced by sensors to monitor the cell culture environment and is operated via "UNICORN" control software. The system was designed to deliver reliable and accurate performance for research, process development, or manufacturing operations.

Eric Roman, general manager of research and applied markets at GE Healthcare, said, “Through our scale and innovation, we are committed to addressing the significant challenges that remain in moving from highly promising experimental cell therapies to widely available and affordable treatments. We have an extensive research program, working with leaders in the field such as the Karolinska University Hospital, (Stockholm, Sweden) to develop tailored technologies and workflows. The focus of our Xuri technology family is to enable the safe, reliable, and efficient progress of cell therapies from clinical development to commercialization.”

Related Links:

GE Healthcare
Karolinska University Hospital



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.